par Trepo, Eric 
;Potthoff, Andrej;Pradat, Pierre;Bakshi, Rakesh;Young, Bradford;Lagier, Robert;Moreno, Christophe ;Verset, Laurine ;Cross, Richard;Degré, Delphine ;Lemmers, Arnaud ;Gustot, Thierry ;Berthillon, Pascale;Rosenberg, William;Trepo, Christian;Sninsky, John;Adler, Michael ;Wedemeyer, Heiner
Référence Journal of hepatology, 55, 1, page (38-44)
Publication Publié, 2011-07
;Potthoff, Andrej;Pradat, Pierre;Bakshi, Rakesh;Young, Bradford;Lagier, Robert;Moreno, Christophe ;Verset, Laurine ;Cross, Richard;Degré, Delphine ;Lemmers, Arnaud ;Gustot, Thierry ;Berthillon, Pascale;Rosenberg, William;Trepo, Christian;Sninsky, John;Adler, Michael ;Wedemeyer, HeinerRéférence Journal of hepatology, 55, 1, page (38-44)
Publication Publié, 2011-07
Article révisé par les pairs
| Résumé : | Fibrosis progression in patients with chronic hepatitis C (CHC) is highly variable. A Cirrhosis Risk Score (CRS) based on seven genetic variants has been recently developed for identifying patients at risk for cirrhosis. The objective of this study was to assess the role of the CRS for the early prediction of fibrosis progression in CHC patients with mild liver fibrosis. In addition, we evaluated the potential benefit, for prediction accuracy, of a recently described non-invasive fibrosis staging assay, the Enhanced Liver Fibrosis (ELF) test. |
